Physician profile
Tracy Hooper
NPI 1619962206
$5,733.16
in general payments reported to CMS, 2019-2025
37 companies · $984 in 2025
The $984 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,176 · 2022: $1,303 · 2023: $990 · 2024: $1,280 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,254.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.38 | 2021-2025 | |
| Amgen INC. | $572.37 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $560.44 | 2021-2025 | |
| Novo Nordisk INC | $461.62 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $341.12 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.01 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $304.50 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $284.88 | 2022-2025 | |
| Glaxosmithkline, LLC. | $232.53 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $183.34 | 2024-2025 | Gemtesa |
| Medtronic, INC. | $183.33 | 2022-2024 | Kyphon Express II Kyphopak Tray |
| Axsome Therapeutics, INC. | $169.06 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $145.00 | 2021-2024 | Veozah |
| Lilly USA, LLC | $119.96 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.04 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.